113 related articles for article (PubMed ID: 29871545)
1. Safety of dose-reduced pemetrexed in patients with renal insufficiency.
Hill J; Vargo C; Smith M; Streeter J; Carbone DP
J Oncol Pharm Pract; 2019 Jul; 25(5):1125-1129. PubMed ID: 29871545
[TBL] [Abstract][Full Text] [Related]
2. Estimated Creatinine Clearance Rate Is Associated With the Treatment Effectiveness and Toxicity of Pemetrexed As Continuation Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Chen CY; Lin JW; Huang JW; Chen KY; Shih JY; Yu CJ; Yang PC
Clin Lung Cancer; 2015 Nov; 16(6):e131-40. PubMed ID: 25659505
[TBL] [Abstract][Full Text] [Related]
3. A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non-Small-Cell Lung Cancer.
Ellis PM; Leighl NB; Hirsh V; Reaume MN; Blais N; Wierzbicki R; Sadrolhefazi B; Gu Y; Liu D; Pilz K; Chu Q
Clin Lung Cancer; 2015 Nov; 16(6):457-65. PubMed ID: 26100229
[TBL] [Abstract][Full Text] [Related]
4. Effect of renal function on pemetrexed-induced haematotoxicity.
Ando Y; Hayashi T; Ujita M; Murai S; Ohta H; Ito K; Yamaguchi T; Funatsu M; Ikeda Y; Imaizumi K; Kawada K; Yasuda K; Yamada S
Cancer Chemother Pharmacol; 2016 Jul; 78(1):183-9. PubMed ID: 27286996
[TBL] [Abstract][Full Text] [Related]
5. Preliminary Safety, Pharmacokinetics, and Efficacy of Regorafenib, Cisplatin, and Pemetrexed in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancers.
Hellmann MD; Sturm I; Trnkova ZJ; Lettieri J; Diefenbach K; Rizvi NA; Gettinger SN
Clin Lung Cancer; 2015 Nov; 16(6):514-22. PubMed ID: 26003007
[TBL] [Abstract][Full Text] [Related]
6. [Analysis of Pemetrexed Monotherapy in Advanced Non-Small Cell Lung Cancer Patients with Impaired Renal Function].
Funaguchi N; Nakajima Y; Kaito D; Yanase K; Ito F; Endo J; Morishita M; Asano M; Iihara H; Mori H; Ohno Y; Minatoguchi S
Gan To Kagaku Ryoho; 2015 Jun; 42(6):705-8. PubMed ID: 26199241
[TBL] [Abstract][Full Text] [Related]
7. Toxicity of pemetrexed during renal impairment explained-Implications for safe treatment.
Boosman RJ; Dorlo TPC; de Rouw N; Burgers JA; Dingemans AC; van den Heuvel MM; Hendriks LEL; Biesma B; Aerts JGJV; Croes S; Mathijssen RHJ; Huitema ADR; Ter Heine R
Int J Cancer; 2021 Oct; 149(8):1576-1584. PubMed ID: 34181276
[TBL] [Abstract][Full Text] [Related]
8. Second-line pemetrexed treatment in Taiwanese patients with advanced nonsmall cell lung cancer: an open-label single-arm study.
Chang GC; Tsai CM; Hsia TC; Yang CH; Abdulnabi R; Blair JM; Linn C
J Formos Med Assoc; 2013 Sep; 112(9):518-26. PubMed ID: 24060197
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group.
Shepherd FA; Dancey J; Arnold A; Neville A; Rusthoven J; Johnson RD; Fisher B; Eisenhauer E
Cancer; 2001 Aug; 92(3):595-600. PubMed ID: 11505404
[TBL] [Abstract][Full Text] [Related]
10. Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG).
Kentepozidis N; Economopoulou P; Christofyllakis C; Chelis L; Polyzos A; Vardakis N; Koinis F; Vamvakas L; Katsaounis P; Kalbakis K; Nikolaou C; Georgoulias V; Kotsakis A
Clin Transl Oncol; 2017 Mar; 19(3):317-325. PubMed ID: 27492015
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation.
Yoshimura N; Kudoh S; Mitsuoka S; Yoshimoto N; Oka T; Nakai T; Suzumira T; Matusura K; Tochino Y; Asai K; Kimura T; Kawaguchi T; Hirata K
Lung Cancer; 2015 Oct; 90(1):65-70. PubMed ID: 26238424
[TBL] [Abstract][Full Text] [Related]
12. Feasibility study of first-line chemotherapy using Pemetrexed and Bevacizumab for advanced or recurrent nonsquamous non-small cell lung cancer in elderly patients: TORG1015.
Kozuki T; Nogami N; Kitajima H; Iwasawa S; Sakaida E; Takiguchi Y; Ikeda S; Yoshida M; Kato T; Miyamoto S; Sakamaki K; Shinkai T; Watanabe K
BMC Cancer; 2016 May; 16():306. PubMed ID: 27177035
[TBL] [Abstract][Full Text] [Related]
13. A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer.
Rodrigues-Pereira J; Kim JH; Magallanes M; Lee DH; Wang J; Ganju V; MartÃnez-Barrera L; Barraclough H; van Kooten M; Orlando M
J Thorac Oncol; 2011 Nov; 6(11):1907-14. PubMed ID: 22005471
[TBL] [Abstract][Full Text] [Related]
14. A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.
Soria JC; Adjei AA; Bahleda R; Besse B; Ferte C; Planchard D; Zhou J; Ware J; Morrissey K; Shankar G; Lin W; Schutzman JL; Dy GK; Groen HJM
Eur J Cancer; 2017 Nov; 86():186-196. PubMed ID: 28992562
[TBL] [Abstract][Full Text] [Related]
15. CHAMP: A Phase II Study of Panitumumab With Pemetrexed and Cisplatin Versus Pemetrexed and Cisplatin in the Treatment of Patients With Advanced-Stage Primary Nonsquamous Non-Small-Cell Lung Cancer With Particular Regard to the KRAS Status.
Schuette W; Behringer D; Stoehlmacher J; Kollmeier J; Schmager S; Fischer von Weikersthal L; Schumann C; Buchmann J
Clin Lung Cancer; 2015 Nov; 16(6):447-56. PubMed ID: 26094080
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents.
Shukuya T; Ko R; Mori K; Kato M; Yagishita S; Kanemaru R; Honma Y; Shibayama R; Koyama R; Shimada N; Takahashi K
Cancer Chemother Pharmacol; 2015 Oct; 76(4):771-6. PubMed ID: 26259641
[TBL] [Abstract][Full Text] [Related]
17. Pemetrexed: a multitargeted antifolate.
Rollins KD; Lindley C
Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer.
Davies AM; Ho C; Metzger AS; Beckett LA; Christensen S; Tanaka M; Lara PN; Lau DH; Gandara DR
J Thorac Oncol; 2007 Dec; 2(12):1112-6. PubMed ID: 18090584
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of induction chemotherapy of pemetrexed plus split-dose cisplatin followed by pemetrexed maintenance for untreated non-squamous non-small-cell lung cancer.
Koba T; Minami S; Nishijima-Futami Y; Masuhiro K; Kimura H; Futami S; Yaga M; Mori M; Kagawa H; Uenami T; Kohmo S; Otsuka T; Yamamoto S; Komuta K; Kijima T
Cancer Chemother Pharmacol; 2018 Jul; 82(1):111-117. PubMed ID: 29728800
[TBL] [Abstract][Full Text] [Related]
20. Dose escalation and pharmacokinetic study of carboplatin plus pemetrexed for elderly patients with advanced nonsquamous non-small-cell lung cancer: Kumamoto thoracic oncology study group trial 1002.
Sakata S; Sasaki J; Saeki S; Hamada A; Kishi H; Nakamura K; Tanaka H; Notsute D; Sato R; Saruwatari K; Iriki T; Akaike K; Fujii S; Hirosako S; Kohrogi H
Oncology; 2015; 88(4):201-7. PubMed ID: 25502447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
